Recent Updates — FMCQF

Fresenius Medical Care reported third-quarter revenue of EUR 4,937 million, a 1% increase year-over-year, driven by growth in its Care Delivery and Care Enablement segments. Reported operating income declined 19% to EUR 384 million due to one-time costs related to the China strategy refinement, while net income fell 42% to EUR 160 million. Excluding special items, operating income decreased 5% to EUR 545 million and basic EPS remained flat at EUR 1.11. The company narrowed its full-year 2026 operating income outlook to between flat and a negative mid-single digit percent growth rate, citing regulatory headwinds and inflation. Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases.

Fresenius Medical Care's Supervisory Board unanimously appointed Shervin J. Korangy as Chief Executive Officer and Chair of the Management Board, effective October 12, 2026. He succeeds Helen Giza, who served as CEO for four years after previously acting as CFO. Korangy, a former member of the company's Supervisory Board since 2023, brings extensive healthcare leadership experience from his tenure as CEO of BVI Medical and roles at Novartis and Blackstone. The appointment marks a strategic transition to accelerate long-term profitable growth following the successful implementation of the FME25+ transformation program, which reduced costs by approximately EUR 1.2 billion. Ann Custin has been identified as Korangy's successor on the Supervisory Board. Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases.

Fresenius Medical Care announced refinements to its China commercial strategy, focusing on a localized portfolio and discontinuing production of the 4008A hemodialysis system while exiting its peritoneal dialysis business. The company appointed Rex Liu as market General Manager to strengthen local leadership. These actions are expected to result in one-time costs of approximately €110 million, primarily for impairment charges and scrappage, recognized as a special item in Q3 2026. The adjustment is not expected to meaningfully impact future revenue outlooks for the China business. Fresenius Medical Care operates in the healthcare industry, providing dialysis products and services for patients with renal diseases.